Last reviewed · How we verify
VB4-845 Injection
VB4-845 is an anti-VEGF/HER2 bispecific antibody that simultaneously targets vascular endothelial growth factor and human epidermal growth factor receptor 2 to inhibit tumor angiogenesis and block HER2-driven proliferation.
VB4-845 is an anti-VEGF/HER2 bispecific antibody that simultaneously targets vascular endothelial growth factor and human epidermal growth factor receptor 2 to inhibit tumor angiogenesis and block HER2-driven proliferation. Used for HER2-positive gastric cancer, HER2-positive breast cancer.
At a glance
| Generic name | VB4-845 Injection |
|---|---|
| Sponsor | Qilu Pharmaceutical Co., Ltd. |
| Drug class | Bispecific monoclonal antibody |
| Target | VEGF and HER2 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
VB4-845 functions as a bispecific monoclonal antibody designed to engage two distinct oncogenic pathways simultaneously. By binding both VEGF and HER2, it prevents tumor neovascularization while directly inhibiting HER2-mediated cancer cell growth, potentially overcoming resistance mechanisms associated with single-target therapies.
Approved indications
- HER2-positive gastric cancer
- HER2-positive breast cancer
Common side effects
- Infusion-related reactions
- Hypertension
- Diarrhea
- Nausea
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VB4-845 Injection CI brief — competitive landscape report
- VB4-845 Injection updates RSS · CI watch RSS
- Qilu Pharmaceutical Co., Ltd. portfolio CI